Drug Database
PI

piperacillin (piperacillin, KRKA / Isipen)

✓ Approved

Krka · 小分子 · 小分子

什么是 piperacillin?

piperacillin 是一种小分子,由Krka研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名piperacillin, KRKA, Isipen
公司Krka
药物类别小分子
给药途径Unknown
状态Approved

治疗适应症

piperacillin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsSalmonellosis✓ Approved

相关研究文献

PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-11-16

Interpreting the Mortality Difference Between Cefepime and Piperacillin-Tazobactam in Pseudomonas aeruginosa Pneumonia.

Regina Jean J, Brahier Thomas T, Sohani Zahra N ZN, McDonald Emily G EG et al.

PMID 43036123
阅读全文 →
PubMedAntimicrobial stewardship & healthcare epidemiology : ASHE2026-11-15

An evaluation of piperacillin-tazobactam antimicrobial stewardship intervention and association with β-lactam susceptibility in Pseudomonas aeruginosa and Enterobacter cloacae complex.

Geneva Ivayla I II, Medugbon Kayode K, Thomas Stephen J SJ, Call Andrea A

Antimicrobial resistance is a growing global concern. At our hospital, susceptibility of Pseudomonas aeruginosa to piperacillin-tazobactam declined from 95% to 77%, while susceptibility of Enterobacter cloacae complex decreased from 82% to 72%, prompting antimicrobial stewardship program (ASP) interventions. ASP interventions aimed to reduce unnecessary antipseudomonal therapy with ceftriaxone recommended for low-risk patients, to replace piperacillin-tazobactam with cefepime in high-risk patients. Additionally, pharmacodynamic optimization was introduced for piperacillin-tazobactam, cefepime, and ceftriaxone. Annual inpatient antibiograms and antibiotic use (days of therapy per 1,000 patient-days) were evaluated for piperacillin-tazobactam, cefepime, meropenem, ciprofloxacin, levofloxacin, and ceftriaxone. Spearman correlation assessed the relationship between antibiotic use and bacterial susceptibility with a 1-year lag. Over the two years following the initiation of interventions in 2023, piperacillin-tazobactam use decreased 11-fold, cefepime use increased 2.6-fold, and ceftriaxone use increased by 1.7-fold. Meropenem use declined 1.5-fold. P. aeruginosa susceptibility improved: piperacillin-tazobactam (77% to 96%), meropenem (83% to 92%), and cefepime (77% to 96%). E. cloacae complex susceptibility to piperacillin-tazobactam increased from 63% to 86%. Piperacillin-tazobactam use demonstrated a statistically significant perfect negative correlation with P. aeruginosa susceptibility. Cefepime use showed a strong positive, non-significant correlation with P. aeruginosa susceptibility, whereas the correlation between piperacillin-tazobactam use and E. cloacae susceptibility was moderately negative but not significant. ASP-driven restriction of piperacillin-tazobactam was associated with marked improvement in P. aeruginosa susceptibility to both piperacillin-tazobactam and cefepime despite substantially increased cefepime use, suggesting shared resistance mechanisms and that piperacillin-tazobactam may be a major driver of resistance selection.

PMID 43032287
阅读全文 →
PubMedDrug, healthcare and patient safety2026-11-15

Severe Piperacillin/Tazobactam-Induced Liver Injury: A Case Report and Literature Review.

Yu Fei F, Chen Xiaomei X, Jiang Na N, Zhang Ye Y

Piperacillin/tazobactam is a broad-spectrum antibiotic primarily indicated for the treatment of moderate-to-severe polymicrobial infections. Severe drug-induced liver injury (DILI) is a rare adverse event attributed to its use. We report the case of a 79-year-old male patient who underwent radical resection for rectal cancer and postoperatively received antineoplastic therapy. Due to the development of fever and surgical site infection, he was started on intravenous piperacillin/tazobactam. Twelve days after treatment initiation, the patient exhibited significantly elevated liver biochemical parameters, and an abnormal eosinophil percentage was noted on day 16. Despite interventions with hepatoprotective agents and glucocorticoids, his hepatic parameters continued to deteriorate, accompanied by jaundice of the skin and sclera. Integrating imaging, laboratory findings, and medication history, the multidisciplinary team suspected piperacillin/tazobactam-induced cholestatic DILI (R value < 2), with jaundice indicating potentially severe liver injury. Piperacillin/tazobactam was immediately discontinued, and hepatoprotective therapy was continued. The patient's liver function gradually improved, with liver enzymes and bilirubin levels returning to normal or near-normal by day 106 post-withdrawal. The causality assessment was determined as "probable" based on the Naranjo Adverse Drug Reaction Probability Scale (score 7) and the Roussel Uclaf Causality Assessment Method (score 8). Additionally, we reviewed the literature regarding the clinical manifestations, pathogenesis, susceptible genes, biomarkers, and treatment principles of piperacillin/tazobactam-induced DILI. As a rare yet severe adverse drug reaction, DILI demands heightened vigilance, early recognition, and effective management. Crucially, immediately stopping the suspected drug remains the paramount intervention once DILI is suspected. The underlying mechanisms, genetic predispositions, and specific biomarkers associated with piperacillin/tazobactam-induced DILI remain to be fully elucidated, underscoring the need for further investigation.

PMID 43032256
阅读全文 →
PubMedAntimicrobial stewardship & healthcare epidemiology : ASHE2026-11-15

Effect of a 7-Day and 14-Day Antibiotic Time-Out Reminder Alert (TORA) on Inpatient Piperacillin-Tazobactam Use: an interrupted time-series study.

Suzuki Yuhei Y, Yamaguchi Ryo R, Yamamoto Takehito T, Harada Sohei S et al.

To evaluate whether a low-burden antimicrobial stewardship intervention, the 7-Day and 14-Day Antibiotic Time-Out Reminder Alert (TORA), was associated with changes in inpatient piperacillin-tazobactam (PIPC/TAZ) use. Quasi-experimental interrupted time-series study. A tertiary-care teaching hospital in Japan. Inpatients in targeted departments, excluding hematology and transplant surgery. TORA was introduced on September 1, 2021, using day-7 and day-14 reminders for ongoing PIPC/TAZ therapy in the electronic medical record. The primary outcome was monthly PIPC/TAZ use as days of therapy (DOT) per 100 patient-days. Segmented regression analysis used generalized least squares with a first-order autoregressive correlation structure and month fixed effects. Balancing outcomes included carbapenems, antipseudomonal cephalosporins, and quinolones. Secondary outcomes included treatment episodes lasting ≥7 and ≥14 days and 30- and 90-day mortality. TORA was associated with an immediate reduction in PIPC/TAZ use (level change, -1.021 DOT/100 patient-days; 95% CI, -1.783 to -0.259; P = .010) but no significant change in postintervention slope (-0.007 DOT/100 patient-days per month; 95% CI, -0.044 to 0.031; P = .724). Carbapenem and quinolone use showed no significant immediate or slope changes, whereas antipseudomonal cephalosporin use decreased immediately without slope changes. The proportions of treatment episodes lasting ≥7 and ≥14 days decreased significantly. Thirty- and 90-day mortality did not differ significantly before and after implementation. A low-burden TORA strategy was associated with an immediate reduction in inpatient PIPC/TAZ use and may offer a pragmatic stewardship approach where personnel-intensive interventions are difficult to sustain.

PMID 43031932
阅读全文 →
PubMedInfection and drug resistance2026-11-15

Cryptogenic Invasive Klebsiella pneumoniae Liver Abscess Syndrome with Occult Colon Cancer: A Case Report.

Wang Ni N, Yang Jinsun J, Wei Meng M, Quan Bin B

Invasive Klebsiella pneumoniae liver abscess syndrome (IKLAS) describes K. pneumoniae liver abscess with extrahepatic metastatic infection. Although the syndrome is associated with hypervirulent K. pneumoniae (hvKP), its clinical presentation alone does not confirm hypervirulence. Occult colorectal malignancy may be identified during evaluation of apparently cryptogenic infection. A 75-year-old man presented with intermittent fever for more than 1 month and right upper abdominal pain. Imaging revealed multiple hepatic abscesses and pulmonary lesions compatible with metastatic infection. K. pneumoniae was isolated from blood and sputum cultures, supporting a clinical diagnosis of IKLAS. Hypervirulence was clinically suspected but not microbiologically confirmed because capsular serotyping and virulence-gene testing were not performed. The patient had no history of diabetes mellitus or biliary tract disease. Abdominal CT showed irregular wall thickening at the hepatic flexure, and colonoscopy with biopsy confirmed moderately to poorly differentiated adenocarcinoma. Piperacillin-tazobactam and moxifloxacin were associated with clinical improvement and radiologic regression; percutaneous drainage was deferred because of incomplete abscess liquefaction. After infection control, he underwent laparoscopic radical right hemicolectomy (pathological stage pT3N0Mx). No recurrence or distant metastasis was detected at the 9-month postoperative follow-up. This case illustrates that apparently cryptogenic IKLAS may be an initial clinical clue to occult colon cancer. Individualized colorectal evaluation may be considered, particularly in patients without common predisposing factors or with suspicious clinical or imaging findings. This single case does not establish causality or support universal screening.

PMID 43034784
阅读全文 →
PubMedAntimicrobial stewardship & healthcare epidemiology : ASHE2026-11-15

Cumulative antibiogram at a tertiary cancer center in Jordan showing alarming antimicrobial resistance trends.

Mubarak Sawsan S, Sultan Iyad I, Abu Ata Osama O, Khresat Omar O et al.

Multidrug-resistant (MDR) bacteria poses a significant threat to patient care, especially in vulnerable populations. This study evaluates antimicrobial resistance (AMR) trends at a tertiary cancer center in Jordan, analyzing data from 2007 to 2022. This retrospective study analyzed 51,697 first bacterial isolates from 108,432 cultures at King Hussein Cancer Center (2007-2022). Data were stratified into three periods and processed using the AMR package for R. Binomial logistic regression models were employed to forecast resistance trends to 2030. The comprehensive analysis of 51,697 first bacterial isolates revealed that 61% were Gram-negative bacteria (GNB) and 39% were Gram-positive bacteria (GPB), with Escherichia coli, coagulase-negative staphylococci (CoNS), and Klebsiella pneumonia predominating. MDR was identified in 36.5% of isolates, with GNB accounting for 84.4%, while extensively drug-resistant (XDR) was confined to Acinetobacter baumannii-calcoaceticus and Pseudomonas aeruginosa. Conversely, nonfermenting GNB showed declining resistance trajectories for piperacillin/tazobactam and amikacin. Among Gram-positives, methicillin-resistant Staphylococcus aureus (MRSA) surged from 37% to 57%. Vancomycin-resistant enterococci (VRE) increased reaching 13%. Blood cultures were predominantly GPB (65%), while respiratory and urine samples were primary sources of resistant GNB. Hematologic malignancy patients exhibited the highest extensively drug-resistant (XDR) rates (5.6%-7.9%) and VRE burden (32% in leukemia). Predictive models forecast escalations by 2030: MRSA 72.7%, VRE in Enterococcus faecium 70%, and cefepime resistance in Enterobacterales 61.9%. Our AMR patterns are alarming and vary significantly by specimen site and cancer diagnosis, underscoring the urgent need for enhanced stewardship, infection control, and diagnosis-specific empirical protocols.

PMID 43032313
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多piperacillin